Skip to main content
SpringerLink
Log in

Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer

  • Selected Papers of the 5th Congress of the European Society of Urological Oncology and Endocrinology, August 18–20, 1986, Edinburgh, UK
  • Published:
Urological Research Aims and scope Submit manuscript

Summary

Development of androgen-independent prostatic cancer cells from androgen-responsive cells can occur by a variety of mechanisms (e.g., environmental adaptation, multifocal origin, or genetic instability). Regardless of the mechanism of development, however, once androgen-independent cancer cells become present within prostatic cancer, the tumor is no longer homogeneous but is now heterogeneous. Once a prostatic cancer is heterogeneously composed of both androgen-dependent and-independent cancer cells, androgen withdrawal therapy, no matter how complete, cannot be curative. In order to produce cures of such heterogeneous prostatic cancers, hormonal therapy must be combined simultaneously with chemotherapy early in the course of the disease so that all the cancer populations (i.e., androgen-dependent and-independent) can be simultaneously affected within an individual patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Beland J, Elhilali M, Fradet Y, Llaroche B, Ramsey EW, Venner PM (1986) Total androgen blockade vs. orchiectomy in stage D2 prostatic cancer. In: Murphy G (ed) Second international symposium on prostatic cancer. Alan R Liss, New York (in press)

    Google Scholar 

  2. Byar DP, Mostofi FK (1972) Carcinoma of the prostate: Prognostic evaluation of certain pathological features in 208 radical prostatectomies, examined by the step section technique. Cancer 30:5–13

    CAS  PubMed  Google Scholar 

  3. Devesa SS, Silverman DT (1978) Cancer incidence and morbidity trends in the United States: 1935–1974. Natl Cancer Inst 60:545–571

    Google Scholar 

  4. Elder JS, Gibbons SRP (1985) Results of trends of the USA National Prostatic Cancer Project. Prog Clin Biol Res 185(A): 221–242

    Google Scholar 

  5. Ellis WJ, Isaacs JT (1985) Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinoma. Cancer Res 45:6041–6050

    Google Scholar 

  6. Giuliani L, Pescatore D, Giberti C, Martorana G, Natta G (1980) Treatment of advanced prostatic carcinoma with Cyproterone acetate and orchiectomy. 5 year follow-up. Eur Urol 6:145–148

    Google Scholar 

  7. Isaacs JT, Coffey DS (1981) Adaptation vs. selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 41:5070–5075

    Google Scholar 

  8. Isaacs JT (1982a) Hormonally responsive versus unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and-G rat adenocarcinomas. Cancer Res 42:5010–5014

    Google Scholar 

  9. Isaacs JT, Wake N, Coffey DS, Sandberg AA (1982b) Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res 42:2353–2361

    Google Scholar 

  10. Isaacs JT (1984) The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 5:1–18

    Google Scholar 

  11. Isaacs JT (1985) New principles in the management of metastatic prostatic cancer. Prog Clin Biol Res 185(A):383–406

    Google Scholar 

  12. Isaacs JT (1986a) The effects of increasing the rate of cell death on the curability of prostatic cancer by chemotherapy as studied with the Dunning R-3327-G rat prostatic adenocarcinoma (submitted for publication)

  13. Issacs JT (1986b) Control of cell proliferation and cell death in the normal and neoplastic prostate: A stem cell model. NIADDK Monograph BPH (in press)

  14. Karr JP, Murphy GP (1985) Treatment of prostatic carcinoma with combinations of drugs and hormones. In: Bruchovsky N, Chapdelaine A, Newman F (eds) Regulation of androgen action: the proceedings of an international symposia in Montreal. Congressdruck R. Bruchner, West-Berlin, pp 81–86

  15. Kastendieck H (1980) Correlation between atypical primary hyperplasia and carcinoma of the prostate. Histologic studies on 180 total prostatectomies due to manifest carcinoma. Pathol Res Pract 169:366–387

    Google Scholar 

  16. Kirchhiem D, Niles NR, Frankus E, Hodges CV (1966) Correlative histochemical and histological studies on thirty radical prostatectomy specimens. Cancer 19:1683–1696

    Google Scholar 

  17. Labrie F, Dupont A, Belanger A, Lacourciere Y, Raynaud JP, Hassan JM, Gareau J, Fazekos AT, Sandow J, Monfette G, Girard JH, Emond J, Houle J (1983) New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens. Prostate 4:579–594

    Google Scholar 

  18. Labrie F, Dupont A, Belanger A (1985) Complete androgen blockade for the treatment of prostate cancer. In: Devita VT, Hellman S, Rosenberg S (eds) Important advances in oncology 1985. JB Lippincott, Philadelphia, pp 193–217

    Google Scholar 

  19. Labrie F, Belanger A, Dupont A, Emond J, Lacourciere Y, Monfette G (1984) Combined treatment with LHRH agonist and pure antiandrogen in advanced carcinoma of the prostate. Lancet II:1090

    Google Scholar 

  20. Labrie F, Dupont A, Belanger A, Giguere M, Lacourciere Y, Emond Jj, Monfette G, Bergeron V (1985) Combination therapy with Flutamide and castration (LHRH agonist or orchiectomy) in advanced prostatic cancer: a marked improvement in response and survival. J Steroid Biochem 23:833–841

    Google Scholar 

  21. Labrie F, Dupont A, Lacourciere Y, Giguere M, Belanger A, Monfette G, Emond J (1986a) Combined treatment with Flutamide in association with medical or surgical castration. J Urol 135:203A

  22. Labrie F, Veilleux R (1986b) A wide range of sensitivities to androgen develop in clonal Shionogi mouse mammary tumor cells. Prostate 8:293–300

    Google Scholar 

  23. Lepor H, Ross A, Walsh PC (1982) The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol 128:335–340

    Google Scholar 

  24. The Leuprolide Study Group (1984) Leuprolide versus diethylstilbestrol for metastatic prostatic cancer. N Engl J Med 311:1281–1286

    Google Scholar 

  25. Menon M, Walsh PC (1979) Hormonal therapy for prostatic cancer. In: Murphy GP (ed) Prostatic cancer. PSG Publishing, Littleton, Mass, pp 175–200

    Google Scholar 

  26. Mostofi FK, Sesterhenn J (1981) The role of prostatic acid phosphatase in histological diagnosis of carcinoma of the prostate. Proceeding of the Seventy-Sixth Annual Meeting of the American Urological Association, Abstract #42

  27. Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194:23–28

    Google Scholar 

  28. Oesterling JE, Epstein JI, Walsh PC (1986) The inability of adrenal androgens to stimulate the adult human prostate — An autopsy evaluation of men with hypogonadotrophic hypogonadism and panhypopituitarism. J Urol (in press)

  29. Prout GR, Leiman B, Daly JJ, MacLoughlin RA, Griffin PP, Young HH (1976) Endocrine changes after diethylstilbestrol therapy. Urology 7:148–155

    Google Scholar 

  30. Redding TW, Schally AV (1985) Investigation of the combination of the agonist D-Trp-6-LHRH and the antiandrogen Flutamide in the treatment of Dunning R-3327-H prostatic cancer model. Prostate 6:219–232

    Google Scholar 

  31. Schroeder FH, Klijn JG, deJorg FA (1986) Metastatic cancer of the prostate managed by Buserelin acetate versus Buserelin acetate plus Cyproterone acetate. J Urol 135:202A

    Google Scholar 

  32. Schulze H, Isaacs JT, Coffey DS (1986a) A critical review of the concept of total androgen ablation in the treatment of prostatic cancer. In: Murphy G (ed) Second international symposium on prostatic cancer. Alan R Liss, New York (in press)

    Chapter  Google Scholar 

  33. Scott WW, Menon M, Walsh PC (1980) Hormonal therapy of prostatic cancer. Cancer 45:1929–1936

    Google Scholar 

  34. Servadio C, Mukamel E, Kahan E (1984) Carcinoma of the prostate in Israel: Some epidemiological and therapeutic considerations. Prostate 5:375–382

    Google Scholar 

  35. Sinha AA, Blackard CE, Seal US (1977) A critical analysis of tumor morphology and hormone treatments in the untreated and estrogentreated responsive and refractory human prostatic carcinoma. Cancer 40:2836–2850

    Google Scholar 

  36. Smolev JK, Heston WD, Scott WW, Coffey DS (1977) Characterization of the Dunning R-3327-H prostatic adenocarcinoma. An appropriate animal model for prostatic cancer. Cancer Treat Rep 61:273–287

    Google Scholar 

  37. Thompson SA, Johnson MP, Heidger PM, Lubaroff DM (1985) Characterization of the heterogeneity of R-3327 rat prostate tumors derived from single-cell clones Prostate 6:369–387

    Google Scholar 

  38. Viola MV, Fromowitz F, Oravez MS, Deb S, Finket G, Lundy J, Harel P, Thor A, Schlom J (1986) Expression of ras oncogene p21 in prostatic cancer. N Engl J Med 314:133–137

    Google Scholar 

  39. Wake N, Isaacs JT, Sandberg AA (1982) Chromosomal changes associated with progression of the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res 42:4131–4142

    Google Scholar 

  40. Zadra J, Bruce AW, Trachtenberg J (1986) Total androgen ablation therapy in the treatment of advanced prostatic cancer. J Urol 135:201

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

    J. T. Isaacs & N. Kyprianou

  2. The Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

    J. T. Isaacs & N. Kyprianou

Authors
  1. J. T. Isaacs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Kyprianou
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Isaacs, J.T., Kyprianou, N. Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer. Urol. Res. 15, 133–138 (1987). https://doi.org/10.1007/BF00254424

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00254424

Key words

Search

Navigation